European Journal of Clinical Investigation最新文献

{"title":"FNDC4 and FNDC5 Attenuate SARS-CoV-2 S1-Induced Inflammatory Responses in Human Adipose Tissue.","authors":"Gabriela Neira, Julia Hernández-Castañeda, Victoria Catalán, Sara Becerril, Marina Martín, Víctor Valentí, Rafael Moncada, Camilo Silva, Javier Gómez-Ambrosi, Javier Escalada, Gema Frühbeck, Amaia Rodríguez","doi":"10.1111/eci.70215","DOIUrl":"https://doi.org/10.1111/eci.70215","url":null,"abstract":"<p><strong>Background: </strong>Adipose tissue is recognised as a SARS-CoV-2 reservoir and potential infection site. We herein characterised SARS-CoV-2 entry points in visceral (VAT) and subcutaneous (SAT) adipose tissue from people with obesity and determined whether the adipo-myokines FNDC4 and FNDC5 modulate SARS-CoV-2 spike glycoprotein subunit 1 (S1)-induced inflammation in adipocytes and macrophages.</p><p><strong>Methods: </strong>Plasma concentrations of FNDC4, FNDC5 and angiotensin-converting enzyme 2 (ACE2) were measured in 183 participants with obesity and normal weight. Expression of SARS-CoV-2 host cell entry receptors was analysed in paired VAT and SAT biopsies (n = 121). The effects of FNDC4 and FNDC5 on S1-induced inflammatory responses were evaluated in vitro using human visceral adipocytes and THP-1-derived macrophages.</p><p><strong>Results: </strong>Obesity was associated with higher circulating ACE2 and increased expression of SARS-CoV-2 entry receptors (ACE2, CD147, DPP4 and neuropilin-1) in VAT, whereas plasma FNDC4 and FNDC5 levels were reduced. FNDC4, FNDC5 and ACE2 co-localised with macrophage populations in VAT, and FNDC4 and FNDC5 transcripts positively correlated with genes involved in viral entry and priming. Both adipo-myokines attenuated S1-induced M1 macrophage polarisation and HMGB1 secretion and reduced HMGB1 expression in adipocytes.</p><p><strong>Conclusion: </strong>Reduced FNDC4 and FNDC5 levels in obesity may amplify SARS-CoV-2 S1-induced inflammatory responses in VAT macrophages and adipocytes.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70215"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and Prognosis of Patients With Acute Pericarditis in the Emergency Department: A Retrospective, Single-Centre Study.","authors":"Lisa Caldera, Chiara Lovati, Alessandra Vecchié, Walter Ageno, Marco Paolo Donadini, Francesco Dentali, Flavio Tangianu, Aldo Bonaventura","doi":"10.1111/eci.70206","DOIUrl":"https://doi.org/10.1111/eci.70206","url":null,"abstract":"<p><strong>Background: </strong>Despite being a common reason for Emergency Department (ED) admission, information about the management of acute pericarditis is limited in this setting.</p><p><strong>Methods: </strong>In this retrospective study conducted at the ED of Ospedale di Circolo in Varese (Italy) from 2019 to 2023, patients with acute pericarditis were included. The primary endpoint was the occurrence of the 12-month composite outcome (treatment failure, recurrent pericarditis, cardiac tamponade, constrictive pericarditis or death).</p><p><strong>Results: </strong>One-hundred and sixty-nine patients were included (median age 54 years, 65.1% males). Chest pain was the main symptom (96.4%). On admission, aspirin was more frequently given over non-steroidal anti-inflammatory drugs (NSAIDs), and colchicine was prescribed in 40% of patients. At discharge, more patients were prescribed ibuprofen, and colchicine prescription significantly increased to 71%. Drug doses were compliant with guidelines in a limited number of patients at admission and increased at discharge. The composite outcome occurred in 20.1% of patients (n = 34), mainly driven by recurrences (n = 18) and treatment failure. Patients with a complicated course were older, of female sex, with a larger proportion of comorbidities and higher CRP levels. Diabetes (HR 3.9, 95% CI 1.7-9.1), COPD (HR 6.2, 95% CI 2.3-17.1), recent percutaneous cardiac procedures (HR 6.5, 95% CI 2.1-19.6), and recent SARS-CoV-2 vaccination (HR 3.0, 95% CI 1.1-8.2) were independent risk factors for the composite outcome.</p><p><strong>Conclusion: </strong>A significant proportion of patients with acute pericarditis experience long-term complications. Sub-optimal adherence to guideline-recommended doses of anti-inflammatory drugs was commonly observed, suggesting an area for improvement in the management of these patients.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70206"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of miR-150-5p in Human Amniotic Membrane Mesenchymal Cell-Derived Extracellular Vesicles as a Novel Mechanism Driving Cardioprotection.","authors":"Nunzio Alcharani, Laura Tesoro, Javier Díez-Mata, José Luis Zamorano, Marta Saura, Maite Iglesias, Carlos Zaragoza","doi":"10.1111/eci.70212","DOIUrl":"https://doi.org/10.1111/eci.70212","url":null,"abstract":"<p><strong>Background: </strong>Human amniotic membrane mesenchymal stem cells (hAMSCs) hold strong cardioprotective potential, yet their mechanisms of action remain largely elusive.</p><p><strong>Methods and results: </strong>C57BL/6 mice were subjected to cardiac ischemia/reperfusion (I/R) and received intravenous (IV) 2 × 10⁵ hAMSCs at 2, 7 or 14 days post-reperfusion. Cardiac function and MIAT/miR-150/HOXA4 signalling were assessed. Mice treated 2 days post-I/R markedly improved LVEF and reduced myocardial necrosis and fibrosis by Day 21. Minimal hAMSC engraftment, evidenced by SSEA-4 immunostaining, suggests paracrine rather than direct cellular effects. Guided by GWAS implicating miRNAs in myocardial infarction, we identified miR-150 as a key effector, finding that hAMSC upregulated cardiac miR-150 and suppressed HOXA4, a profibrotic target in ischemic myocardium. In parallel, hAMSC treatment reduced cardiac MIAT, a lncRNA that sequesters miR-150, uncovering a mechanism of cardioprotection via MIAT downregulation post-reperfusion. Notably, CRISPR-Cas9 miR-150-silenced hAMSC exhibited severely impaired cardioprotective effects compared to wild-type cells, confirming the functional role of miR-150. miR-150 was identified as a key extracellular vesicle (EV) cargo released by hAMSC under hypoxic conditions, both in vitro and in hAMSC-injected I/R mice. Strickingly, administration of miR-150-enriched EVs to mice recapitulated the therapeutic benefits of hAMSC, underscoring miR-150-5p as central mediator of hAMSC-iduced cardioprotection.</p><p><strong>Conclusions: </strong>hAMSCs promote cardioprotection following I/R via the MIAT/miR-150-5p/HOXA4 axis, in which miR-150-5p plays a central role. These findings provide loss-of-function evidence about the therapeutic potential of hAMSC-derived EVs as a novel cell-free exosome-based strategy for the treatment of acute myocardial infarction.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70212"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prehospital Risk Stratification Using Unsupervised Machine Learning in STEMI.","authors":"Ana Ramos-Rodríguez, Raúl López-Izquierdo, Carlos Del Pozo Vegas, María Plaza-Martín, Cristina Tapia-Ballesteros, Juan F Delgado Benito, Ancor Sanz-García, Francisco Martín-Rodríguez","doi":"10.1111/eci.70214","DOIUrl":"https://doi.org/10.1111/eci.70214","url":null,"abstract":"<p><strong>Background: </strong>ST-elevation myocardial infarction (STEMI) exhibits substantial clinical heterogeneity complicating prehospital risk stratification. Traditional risk assessment tools often fail to capture the complexity of this condition. Machine learning offers opportunities to identify complex clinical patterns not readily apparent during prehospital care.</p><p><strong>Aim: </strong>To identify distinct phenotypes in STEMI patients using unsupervised machine learning algorithms based on prehospital parameters, and to determine their association with short-term mortality and cardiovascular outcomes.</p><p><strong>Methods: </strong>Prospective multicenter observational cohort study including adult patients with prehospital STEMI code activation transported by emergency medical services from January 2022 to August 2025. Only EMS-transported patients were included; those who self-presented to the emergency department were excluded. Prehospital variables, including demographic, clinical, and procedural data, were used for clustering. Factor Analysis of Mixed Data and a two-step clustering: hierarchical clustering (exploring structure and number of clusters) and k-means (clustering assigning patients to phenotypes). A Random Forest classifier with SHapley Additive exPlanations values was used to identify variables contributing to cluster assignment. The primary outcome was 30-day all-cause mortality, assessed through follow-up records.</p><p><strong>Results: </strong>Among 744 patients (median age, 65 years; 76.3% male) unsupervised clustering identified three distinct phenotypes: Phenotype-1 (70.3%) characterized by hemodynamic stability, vessel locations, Killip class I presentation (70.6%), and favourable laboratory parameters; Phenotype-2 (24.3%) presented higher comorbidity burden and metabolic derangements; and Phenotype-3 (5.4%) exhibiting profound hemodynamic instability, severe respiratory failure, out-of-hospital cardiac arrest with return of spontaneous circulation (87.5%), Killip class IV presentation (67.5%), and marked metabolic derangements. The 30-day mortality rates were: 3.4% in Phenotype-1, 22.1% in Phenotype-2, and 75.0% in Phenotype-3.</p><p><strong>Conclusions: </strong>Three clinically distinct STEMI phenotypes were identified with markedly different mortality risks and treatment requirements during prehospital care. Phenotypes derived from readily available prehospital parameters may facilitate early risk stratification, optimize triage decisions, and guide individualized therapeutic strategies.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70214"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic profiling of bile in malignant cholestasis: Analysis of samples collected during EUS-guided biliary drainage.","authors":"Łukasz Krupa, Georges P Schmarz, Robert Staroń, Hartmut H Schmidt, Jacqueline Rehner, Sören L Becker, Marcin Krawczyk","doi":"10.1111/eci.70200","DOIUrl":"https://doi.org/10.1111/eci.70200","url":null,"abstract":"","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70200"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifelong Exercise as a Modulator of CD4⁺ T Cell Immunometabolism.","authors":"Bruna Spolador de Alencar Silva, Amanda Veiga Sardeli, Ricardo R Agostinete, Helena Batatinha, Alessandra Peres, José César Rosa-Neto, José Teixeira, Manuel J Coelho-E-Silva, Paulo J Oliveira, Fábio Santos Lira","doi":"10.1111/eci.70204","DOIUrl":"10.1111/eci.70204","url":null,"abstract":"<p><strong>Background: </strong>It is commonly assumed that aging and chronic low-grade inflammation compromise adaptive immunity, particularly the function and metabolism of CD4⁺ T cells. The preceding are key regulators of immune responses. These immunological alterations contribute to increased susceptibility to infections, diminished vaccine efficacy and the progression of age-related diseases. In contrast, adolescence and young adulthood tend to be characterized by more robust immune responses, though these are heavily influenced by modifiable lifestyle factors such as habitual physical activity, level of cardiorespiratory fitness, diet and body adiposity. Emerging evidence suggests that sustained physical activity throughout life may preserve CD4⁺ T cell competence by favourably modulating their metabolic programming.</p><p><strong>Methods: </strong>The current narrative review explores how lifelong physical exercise impacts CD4⁺ T cell metabolism, with particular emphasis on the developmental window of adolescence and the long-term benefits of early and sustained physical training across the lifespan. Molecular mechanisms linking exercise to metabolic reprogramming of T cells were summarised in parallel with attenuation of immunosenescence and inflammation over the lifespan.</p><p><strong>Results: </strong>This review suggests that lifelong exercise may reprogram CD4⁺ T cell metabolism, enhancing oxidative phosphorylation at rest and glycolytic control upon activation, thereby improving Th17/Treg balance, reducing chronic inflammation and enabling effective effector T cell responses. In this context, exercise initiated early in life may act as a critical modulator by promoting optimal immune function from childhood and establishing a functional peak that helps preserve immune competence during aging.</p><p><strong>Conclusions: </strong>Lifelong and early-life exercise may reprogram CD4⁺ T cell metabolism, strengthening immune balance and preserving immune function during aging.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70204"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Status, Erythropoietin, and Cancer Incidence in the General Population.","authors":"Siem J van Alfen, Pien Rawee, Li Luo, Ilja M Nolte, Bert van der Vegt, Jenny E Kootstra-Ros, Stephan J L Bakker, Ron T Gansevoort, Thera P Links, Wouter T Zandee, Michele F Eisenga","doi":"10.1111/eci.70218","DOIUrl":"10.1111/eci.70218","url":null,"abstract":"<p><strong>Background: </strong>Iron is essential for cellular function and cancer growth. While iron imbalance has been implicated in cancer development, epidemiological evidence remains inconsistent. Erythropoietin (EPO) may influence tumour progression. We aimed to investigate the associations between iron status, EPO levels, and cancer incidence in the general population.</p><p><strong>Method: </strong>Data were obtained from 6109 participants (mean age 52 ± 12 years; 49% male) in the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. Iron biomarkers, including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin and EPO levels, were measured at baseline.</p><p><strong>Results: </strong>Over a median 18.5 year follow-up, 1090 participants developed cancer. Multivariable Cox regression revealed that higher EPO (HR 1.26; 95% CI 1.07-1.47; p = 0.005) was associated with increased overall cancer risk, while elevated hepcidin levels were associated with a lower risk (HR 0.88; 95% CI 0.80-0.96; p = 0.006). Higher sTfR (HR 1.35; 95% CI 1.01-1.80; p = 0.043) was suggestive for an increased risk of overall cancer. After excluding early diagnoses, the increased risk associated with higher EPO levels and decreased risk associated with higher hepcidin levels remained significant. Lower transferrin saturation was associated with increased haematological cancer risk, while higher hepcidin was associated with reduced gastrointestinal cancer risk, especially in women and those with BMI < 25 kg/m². In non-smokers, higher sTfR and EPO were associated with increased overall and kidney cancer.</p><p><strong>Conclusion: </strong>These findings underscore the putative roles of iron metabolism and EPO in cancer, with consistently decreased risks associated with elevated hepcidin levels, particularly among women and individuals with lower BMI.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70218"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Meta-Analysis of Bioadaptor Versus Drug-Eluting Stents in Randomised Trials With Exploratory Single-Arm Landmark Analyses.","authors":"Simon Wölbert, Stephanie Kühne, Andrea Patrignani, Mauro Chiarito, Moritz von Scheidt, Jan Torzewski, Philip Raake, Dario Bongiovanni","doi":"10.1111/eci.70217","DOIUrl":"10.1111/eci.70217","url":null,"abstract":"<p><strong>Background: </strong>Late adverse events after percutaneous coronary intervention continue to occur beyond the first year with last-generation drug-eluting stents (DES). The coronary bioadaptor marks a new approach with an uncaging beginning at approximately 6 months after implantation. We conducted a pairwise meta-analysis of bioadaptor versus DES in randomised trials with complementary single-arm 6-12 and 6-24 landmark analyses.</p><p><strong>Methods: </strong>The systematic review and meta-analysis was conducted according to PRISMA 2020 Guidelines. PubMed, Embase, CENTRAL and Google Scholar were searched for studies reporting clinical outcomes after bioadaptor implantation. The primary outcome was target-lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction and target-lesion revascularisation at 1 year. Secondary outcomes were TLF and individual components at landmark intervals 6-12 and 6-24 months. Single-arm pooled event rates and pairwise comparisons were estimated using generalised linear mixed-effects models.</p><p><strong>Results: </strong>Three randomised trials (n = 2892; 1448 bioadaptor, 1444 DES) were included in pairwise analyses. 1-year TLF showed no significant difference between bioadaptor and DES (OR 0.81, 95% CI 0.51-1.31, I² = 0.0%, p = 0.3943). Likewise, individual components of TLF and device thrombosis did not differ between groups. Ten studies (1753 patients; 1900 lesions) were included in single-arm analyses. Landmark TLF was 0.57% (95% CI 0.07-4.29; I² = 4.6%) from 6 to 12 months and 2.01% (95% CI 0.81-4.92; I² = 74.2%) from 6 to 24 months. Event rates for other endpoints were generally low.</p><p><strong>Conclusions: </strong>No significant differences in safety and efficacy outcomes were observed between bioadaptor and DES. Complementary single-arm landmark analyses suggested low late event rates, but these findings should be interpreted as exploratory. Further randomised trials are warranted.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 5","pages":"e70217"},"PeriodicalIF":3.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13145319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Added Value of GFAP in Patients With Minor Ischemic Stroke","authors":"Andrea Morotti,&nbsp;Mathias Sauer,&nbsp;Francesco Berinato,&nbsp;Marcello Catania,&nbsp;Andrea L. Benedet,&nbsp;Chiara Tolassi,&nbsp;Guglielmo Di Molfetta,&nbsp;Ilaria Pola,&nbsp;Henrik Zetterberg,&nbsp;Nicholas J. Ashton,&nbsp;Andrea Pilotto,&nbsp;Alessandro Padovani","doi":"10.1111/eci.70203","DOIUrl":"10.1111/eci.70203","url":null,"abstract":"","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 4","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging problem of digital and self misuse of obesity management medications: Protecting their clinical value","authors":"Leonilde Bonfrate,&nbsp;Alfredo Caturano,&nbsp;Caterina Conte","doi":"10.1111/eci.70201","DOIUrl":"10.1111/eci.70201","url":null,"abstract":"","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 4","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}